 |
|
Monoclonal antibody reduces exacerbations in asthmatics
October 02, 2006Patients with symptomatic moderate asthma who were treated with anti-tumor necrosis factor alpha, an anti-inflammatory monoclonal antibody, experienced significantly fewer disease exacerbations than individuals taking a placebo.
This research appears in the first issue for October 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
Trevor T. Hansel, M.D., Ph.D., of the National Heart and Lung Institute at Royal Brompton Hospital in London, and 11 associates infused 14 patients with infliximab, a monoclonal antibody that binds and neutralizes tumor necrosis factor alpha (TNFá). Eighteen patients received placebo during the eight-week double-blind study.
According to the investigators, both structured and inflammatory cells in asthmatics can release TNFá, which is an intercellular messenger protein, a cytokine, produced by white blood cells.
"Anti-TNFá therapy has been shown to be effective in patients with rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and psoriasis, but ineffective in patients with chronic obstructive pulmonary disease (COPD)," said Dr. Hansel. "Preliminary reports of efficacy in asthma patients with concomitant rheumatoid arthritis have been encouraging. Small prospective studies of a soluble receptor directed against TNFá in severe refractory asthma have also shown improvements in lung function and airway hyperresponsiveness."
During the study, 13 of the 18 patients on placebo (72 percent) experienced exacerbations, as compared to only four out of 14 patients (29 percent) on infliximab therapy.
All patients in the study cohort continued to use inhaled corticosteroids for their asthma. Study protocol required them to be symptomatic during a two- to four-week run-in period.
After the run-in phase, infusions of either infliximab or placebo were administered at weeks zero, two and six.
"Treatment with infliximab reduced the number of moderate exacerbations in patients with asthma, as monitored by morning and evening use of an electronic spirometer incorporating a clinical diary," said Dr. Hansel. "Although infliximab therapy did not show significant efficacy for the primary endpoint of monitoring peak expiratory flow (PEF), it did produce a significant decrease in the diurnal (during the day) variation in the PEF rate."
(With PEF monitoring, patients take as deep as a breath as possible, then exhale as forcefully as possible into the mouthpiece of the PEF meter for three tests. As a gauge for pulmonary function, it is especially useful in patients older than age five who have persistent moderate to severe asthma.)
"None of the exacerbations we saw in our study warranted treatment with oral corticosteroids or hospitalization, so they cannot be considered to have been severe," said Dr. Hansel.
The researchers noted there were no adverse events associated with using the monoclonal antibody for treatment.
"Given that infliximab therapy was well-tolerated and appeared to reduce the incidence of asthma exacerbations, anti-TNFá therapy merits further study in larger clinical trials in patients with severe asthma," concluded Dr. Hansel.
American Thoracic Society
According to the investigators, both structured and inflammatory cells in asthmatics can release TNFá, which is an intercellular messenger protein, a cytokine, produced by white blood cells.
"Anti-TNFá therapy has been shown to be effective in patients with rheumatoid arthritis, ankylosing spondylitis, Crohn's disease and psoriasis, but ineffective in patients with chronic obstructive pulmonary disease (COPD)," said Dr. Hansel. "Preliminary reports of efficacy in asthma patients with concomitant rheumatoid arthritis have been encouraging. Small prospective studies of a soluble receptor directed against TNFá in severe refractory asthma have also shown improvements in lung function and airway hyperresponsiveness."
During the study, 13 of the 18 patients on placebo (72 percent) experienced exacerbations, as compared to only four out of 14 patients (29 percent) on infliximab therapy.
All patients in the study cohort continued to use inhaled corticosteroids for their asthma. Study protocol required them to be symptomatic during a two- to four-week run-in period.
After the run-in phase, infusions of either infliximab or placebo were administered at weeks zero, two and six.
"Treatment with infliximab reduced the number of moderate exacerbations in patients with asthma, as monitored by morning and evening use of an electronic spirometer incorporating a clinical diary," said Dr. Hansel. "Although infliximab therapy did not show significant efficacy for the primary endpoint of monitoring peak expiratory flow (PEF), it did produce a significant decrease in the diurnal (during the day) variation in the PEF rate."
(With PEF monitoring, patients take as deep as a breath as possible, then exhale as forcefully as possible into the mouthpiece of the PEF meter for three tests. As a gauge for pulmonary function, it is especially useful in patients older than age five who have persistent moderate to severe asthma.)
"None of the exacerbations we saw in our study warranted treatment with oral corticosteroids or hospitalization, so they cannot be considered to have been severe," said Dr. Hansel.
The researchers noted there were no adverse events associated with using the monoclonal antibody for treatment.
"Given that infliximab therapy was well-tolerated and appeared to reduce the incidence of asthma exacerbations, anti-TNFá therapy merits further study in larger clinical trials in patients with severe asthma," concluded Dr. Hansel.
American Thoracic Society
Asthma Current Events and Asthma News RSSExposures to metals and diesel emissions in air linked to respiratory symptoms in children
Exposure shortly after birth to ambient metals from residential heating oil combustion and particles from diesel emissions are associated with respiratory symptoms in young inner city children.
Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later
New research presents strong evidence that the "synergistic" effect of early-life exposure to both outdoor traffic-related pollution and indoor endotoxin causes more harm to developing lungs than one or the other exposure alone.
Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
A protein known to stimulate blood vessel growth has now been found to be responsible for the cell overgrowth in the development of polyps that characterize one of the most severe forms of sinusitis, a study by Johns Hopkins researchers suggests.
Ancestry attracts, but love is blind
People preferentially marry those with similar ancestry, but their decisions are not necessarily based on hair, eye or skin colour.
Common plastics chemicals linked to ADHD symptoms
Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items.
Asthma a significant risk factor for complications in children with H1N1
A new study on pediatric H1N1 influenza admissions has found that asthma is a significant risk factor for severe disease in children with pandemic H1N1 compared with the seasonal flu.
Mother's Depression a Risk Factor in Childhood Asthma Symptoms, Study Suggests
Asthma symptoms can worsen in children with depressed mothers, according to research from Johns Hopkins Children's Center published online in the Journal of Pediatric Psychology.
Sweet -- sugared polymer a new weapon against allergies and asthma
Scientists at Johns Hopkins and their colleagues have developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks.
Pivotal study for PSD502 -- the first potential treatment for premature ejaculation
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).
Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor
This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities.
More Asthma Current Events and Asthma News Articles
 |
Asthma-Free Naturally: Everything You Need to Know to Take Control of Your Asthma - Featuring the Buteyko Breathing Method Suitable for Adults and Children by Patrick McKeown (Author) This revolutionary book teaches readers how to take control of their asthma safely and effectively without any side effects. The approach encompasses the Buteyko Breathing Method as well as guidance on diet, sleep, physical activity, and other lifestyle changes that can provide a natural alternative to Asthma medications. The author was a chronic asthmatic who applied the Buteyko Breathing Method to free himself from his asthma condition. In this book, he details the Buteyko Breathing Method and provides guidance on diet, sleep, physical activity, and other lifestyle changes that can provide a natural alternative to Asthma medications. The Buteyko Breathing Method is considered by many to be the single most effective self-help treatment for asthma and can be used by adults... |
 |
The Original Aroma Therapipe, Salt Pipe, Respiratory and Asthma Aid by Sopipa The salt crystals were formulated millions of years ago when the primal ocean receded and left behind caverns of purified crystal salt. We bring these crystals to you in a quality certified and handmade ceramic container (made in Hungary). A Polish physician in the 19th Century noted that salt minors seldom had respiratory diseases. Since then Eastern Europe has gained a reputation for its Salt Mines, where many people go for the healing, antibacterial and anti-fungal qualities of the caves salty air. Some people have found that the Aroma Therapipe can be used as a preventative. Many also find that the duration of a cold is lessened with its use. Halo/Speleo Therapy (cave / salt therapy) is not well known in the US. even though it has been used for decades in European countries. This... |
 |
The Allergy and Asthma Cure: A Complete 8-Step Nutritional Program by Fred Pescatore M.D. (Author) Free yourself of allergies and asthma once and for all with Dr. Pescatore's breakthrough program " Dr. Fred Pescatore's The Allergy and Asthma Cure reveals a unique and revolutionary understanding of the underlying conditions of allergy and asthma-from food triggers to the environment to nutritional deficiencies. His integrative program of both alternative and traditional treatments can dramatically improve health and vitality, safely and soundly. This book will have a prominent place in my library and I highly recommend it! " -Ann Louise Gittleman, Ph.D., C.N.S., author of the bestselling The Fat Flush Plan "Conventional medicine has largely shrugged its shoulders in confusion about the causes of allergies and asthma in millions of people. In this... |
 |
Primatene Mist Epinephrine Inhalation Aerosol Bronchodilator with Mouthpiece for Oral Inhalation, .5 fl oz (15 ml) by Primatene For the temporary relief of Bronchial Asthma. Contains no sulfites. Made in USA. |
 |
The Asthma Sourcebook 3rd Edition (Sourcebooks) by Francis Adams (Author) "Authoritative, comprehensive." "Logical and straightforward." "[Dr. Adams] succeeds admirably." Written by an award-winning pulmonary specialist and one of New York magazine’s “Best Doctors in New York,” The Asthma Sourcebook explores the latest therapies, medications, diet and nutrition guidelines, and provides you with advice on living with this chronic disorder. This trusted source also examines the challenges of raising children with asthma; debunks commonly held beliefs about food, travel, and exercise; and pinpoints real asthma-causing allergens and how you can avoid them. |
 |
The Harvard Medical School Guide To Taking Control Of Asthma by Christopher H. Fanta (Author), Lynda M. Cristiano (Author), Kenan Haver (Author) Take control of your asthma now wih this easy-to-follow personalized approach Shortness of breath. Tightness in the chest. Wheezing and coughing. These distressing symptoms are a daily fact of life for many of the fifteen million Americans who suffer from asthma, including nearly six million children -- and asthma is on the rise. But even those with severe asthma can lead full, active lives with the help of the experts at Harvard Medical School and Partners Asthma Center. Here is a commonsense guide that includes: Cutting-edge therapies such as anti-IgE therapy and leukotriene-blocking drugs -- as well as complementary and alternative medicine treatments Practice sessions that help you create a personalized program to prepare for acute asthma attacks Plus, special... |
 |
Native Remedies Complete Asthma ComboPack by Native Remedies The ComboPack of BronchoSootohe and BioVent consists of multiple remedies that work well together to provide increased support for your condition. This ComboPack assists with effective prevention and relief of asthma. The BronchoSoothe is a natural asthma remedy that helps to relax and open airways for normal breathing while the BioVent improves respiratory health and to strengthen the chest and improve respiratory functioning and health and both may be combined for optimum results. |
 |
Reversing Asthma: Breathe Easier with This Revolutionary New Program by Richard N. Firshein D.O. (Author) Comprehensive, balanced and up-to-the minute, Reversing Asthma is destined to be the new bible for asthma treatment - giving asthma sufferers new knowledge and new choices for overcoming this frightening and debilitating disease. |
 |
Microlife PF 100 Peak Flow Meter for Spirometry with FEV1 by Microlife This device is used to measure Peak Expiratory Flow (PEF) and Forced Expiratory Volume in 1-second (FEV1) in both children and adults. PEF is the fastest speed air can be blown out of the lungs after inhalation. FEV1 measures the volume after exhaling in 1-second. Peak Flow (PEF) and Forced Expiratory Volume in 1-second (FEV1) measurements can tell how well lungs are breathing by monitoring airflow. Doctors can have patients monitor changes in airflow and record the results. The automatic memory stores and provides easy access to the last 240 readings along with the time and date. |
 |
The Lion Who Had Asthma (Albert Whitman Concept Paperbacks) by Jonathan London (Author), Nadine Bernard Westcott (Illustrator) Sean's nebulizer mask and his imagination aid in his recovery following an asthma attack. Includes information on childhood asthma and how to control its symptoms. |
| © 2009 BrightSurf.com |